Anti-TL1A Deal Benchmarks

Median Upfront

$620M

Range: $326M - $910M

Total Deal Value

$3.3B

Range: $2.1B - $4.5B

Royalty Rate

8.1% - 15.1%

Tiered up to 19.1%

Dev Milestones

$557M

Range: $364M - $750M

Model Your Deal

Market Analysis

TL1A (TNF-like ligand 1A) has become the most sought-after novel target in gastroenterology following Merck's $10.8B acquisition of Prometheus Biosciences in 2023. Phase 2 anti-TL1A deals for Crohn's disease carry a median total deal value of $3.3B, with upfront payments of $620M. The dual mechanism — anti-inflammatory and anti-fibrotic activity — addresses a critical unmet need in IBD, as fibrosis drives surgical morbidity in Crohn's disease.

Deal structures for anti-TL1A assets reflect the transformative pipeline interest. Development milestones average $557M, with key gates tied to endoscopic remission data and fibrosis endpoints. Regulatory milestones of $663M and commercial milestones of $1.4B reward market entry in what is projected to become a $5-10B target class by 2030.

Royalty rates for anti-TL1A licensing range from 8.1% to 15.1%, with tiered escalation to 19.1%. Differentiation factors include biomarker-guided patient selection (TL1A genetic risk variants), combination potential with IL-23 inhibitors, and oral versus injectable formulation. The competitive landscape has expanded rapidly, with Roche/Genentech, Pfizer, AbbVie, and Sanofi all pursuing TL1A programs.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for anti-TL1A licensing?

Phase 2 anti-TL1A deals average $620M upfront with $3.3B total deal value. The $10.8B Merck/Prometheus acquisition has set a high-water mark that influences all subsequent TL1A deal negotiations.

Why is TL1A considered a breakthrough target in GI?

TL1A uniquely combines anti-inflammatory and anti-fibrotic activity, addressing the root cause of surgical morbidity in Crohn's disease. The genetics-guided patient selection approach (TL1A risk variants in ~50% of IBD patients) enables precision medicine strategies with higher response rates. Phase 2 data from tulisokibart showed unprecedented endoscopic remission rates.

How does the anti-TL1A competitive landscape affect deal terms?

The rapid expansion of TL1A programs (10+ in clinical development) has increased competitive pressure but also validated the target, supporting deal premiums. First-movers with clinical data command the highest valuations, while differentiated approaches (bispecific TL1A/IL-23, oral TL1A inhibitors) can maintain premium terms.

What combination strategies drive TL1A deal value?

TL1A + IL-23 inhibitor combinations represent the most anticipated approach, potentially addressing biologic-refractory IBD. Preclinical data suggests synergistic anti-inflammatory and anti-fibrotic effects. Assets with demonstrated combination compatibility command 15-25% premium in total deal value.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Anti-TL1A Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Gastroenterology Deal Overview

IL-23 GI Deal Benchmarks

Bispecific Antibody Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?